Table 4.
Performance Comparison of Mutational Testing in the Present Study to Published Literature
| Present study | Sevem-gene MT | ThyroSeq® v2 | |
|---|---|---|---|
| Sensitivity | |||
| AUS | 85% | 63% | 91% |
| FN | 100% | 57% | 90% |
| Specificity | |||
| AUS | 65% | 99% | 92% |
| FN | 57% | 97% | 93% |
| PPV | |||
| AUS | 50% | 88% | 77% |
| FN | 63% | 87% | 83% |
| NPV | |||
| AUS | 91% | 94% | 97% |
| FN | 100% | 86% | 96% |
| n | |||
| AUS | 44 | 247 | 98 |
| FN | 12 | 214 | 143 |
| Malignancy rate | |||
| AUS | 30% | 14% | 23% |
| FN | 38% | 27% | 27% |